Trading Signals: MNTA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 30, 2020)(Momenta Pharmaceuticals Inc)
| MNTA latest price $28.7700 (3.04%) ($27.4500 - $28.9300) on Wed. Aug. 12, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.23% (three month average) | RSI | 44 | Latest Price | $28.7700(3.04%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | MNTA declines -2.6% a day on average for past five trading days. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support MNTA advance at 0% a week (0% probability) ONLN(17%) UUP(40%) UNG(14%) VXX(5%) TAN(6%) | Factors Impacting MNTA price | MNTA will decline at least -2.115% in a week (0% probabilities). IWD(-53%) DIA(-48%) DRIV(-46%) GLD(-37%) IWN(-31%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.115% (StdDev 4.23%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $17.25(-40.04%) | Resistance Level | $31.24 | 5 Day Moving Average | $30.13(-4.51%) | 10 Day Moving Average | $30.73(-6.38%) | 20 Day Moving Average | $31.24(-7.91%) | To recent high | -26.7% | To recent low | 3% | Market Cap | $3.412b | | | | Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. |